共查询到20条相似文献，搜索用时 15 毫秒
1.
2.
Brandon S. Walker Robert L. Schmidt Sandra K. White Ryan A. Metcalf 《Transfusion》2023,63(9):1719-1727
3.
Marion Vermeulen Ronel Swanevelder Gert Van Zyl Nico Lelie Edward L. Murphy 《Transfusion》2021,61(9):2688-2700
4.
Pratistha Tamrakar Cyrus Bett Ruth Damaris Molano Amna Ayub David M. Asher Luisa Gregori 《Transfusion》2021,61(11):3181-3189
5.
6.
7.
Ana María Ojea Carolina Seco Pablo Mata María del Carmen Muñoz Marta Elena Álvarez Argüelles Francisco Rodríguez-Frías Josep Quer Sivila Ariadna Rando Segura José María García-Gala Mercedes Rodriguez 《Transfusion》2023,63(9):1767-1772
Background
Few cases of transfusion-transmitted hepatitis E virus (HEV) have been published in Spain. Here, we describe a well-characterized lookback investigation of a transfusion-transmitted HEV case at the Community Centre for Blood and Tissues of Asturias (Spain).Case Report
A female patient with chronic myeloid leukemia underwent an allogeneic bone marrow transplant in March 2019 and showed alterations in liver function shortly afterwards. This patient received blood components from 30 different donors in the 3 months before the transplant. Frozen plasma samples from these donations were investigated for the presence of HEV-RNA. One frequent donor was identified as asymptomatic HEV RNA-positive at the time of his whole blood donation. The investigation revealed that this donor's plasma unit, originally intended for the fractionation industry, had a viral RNA concentration of 1.9 × 104 copies/mL. HEV RNA was detected initially in the index patient who received the red cell concentrate from this donor 25 days after the transfusion. HEV RNA isolated from both donor and recipient were identified as subtype 3f. The recipient of platelet concentrate (PC), treated with a riboflavin-based pathogen reduction technology (PRT) was not infected, being negative for the presence of HEV IgM, IgG, and HEV RNA before and after the transfusion.Conclusion
This case study shows that HEV was transmitted through red cell transfusion to a recipient, while the patient who received riboflavin/UV light treated PC did not develop signs of infection. A causal relationship between PRT treatment of the PC and the non-transmission of HEV remains to be established. 相似文献8.
9.
K. L. Davison † B. Dow ‡ J. A. Barbara † P. E. Hewitt† & R. Eglin† 《Transfusion medicine (Oxford, England)》2009,19(1):24-34
summary . The objectives of the study were to describe the introduction of testing blood donations for antibodies to human T-cell lymphotropic virus (anti-HTLV) and to determine the risk of HTLV potentially infectious donations entering the UK blood supply. The rationale for testing was based on (i) evidence of transmission through transfusion in the UK, (ii) the serious nature of HTLV I-associated morbidity and (iii) evidence of infection in UK blood donors. From mid-2002, all blood donations made at UK blood centres were tested in pooled samples using Abbott-Murex HTLV I/II GE 80/81 enzyme immunoassay (EIA). Surveillance data were used to calculate the incidence and prevalence of anti-HTLV and derive estimates of risk. Between August 2002 and December 2006, 106 donations were confirmed positive for anti-HTLV (95 anti-HTLV I and 11 anti-HTLV II). Prevalence was 10-fold higher among donations from new donors than repeat (4·0 and 0·42 per 100 000 donations), and only one repeat donor had evidence of seroconversion. The risk of an HTLV I potentially infectious donation entering the UK blood supply was estimated at 0·11 per million donations (95% confidence interval 0·06 to 0·18). The current very low observed incidence and prevalence among blood donors reflect the very low estimated risk of an HTLV I-positive donation entering the UK blood supply. A change in either the epidemiology of HTLV in UK blood donors or the length of the window period of the test should prompt further review of the risk and a reassessment of anti-HTLV testing in the UK. 相似文献
10.
11.
Wolfgang Rennert Lina Sobh Katie Cormier Jenna Smith Corina Gonzalez 《Transfusion》2021,61(5):1533-1541
12.
13.
14.
15.
16.
17.
目的 分析2002-2010年广州地区无偿献血者血浆抗-HIV阳性率,为制定人类免疫缺陷病毒(HIV)防治策略及招募安全血源提供科学依据.方法 选择2002年1月至2010年12月广州地区无偿献血人群2 119 684例为研究对象.回顾性调查本组献血者血浆抗-HIV检测结果,分析各年间献血者抗-HIV阳性率变化趋势,不同性别、年龄及职业之间抗-HIV阳性率的差异.结果 2002-2010年广州地区无偿献血者总体血浆抗-HIV阳性率为0.018％,2008-2010年则呈递增趋势.其中,男性献血者个体的血浆抗-HIV阳性率明显高于女性,35岁以下年龄组阳性率低于35岁以上组,学生较其他职业人群血浆抗-HIV阳性率低.结论 广州地区血浆抗-HIV阳性率在2002-2010年间稍有上升,应加强对预防HIV感染的宣传教育及防控措施.鼓励符合献血条件的年轻人积极献血将有利于保障临床输血安全. 相似文献
18.
19.
20.
David LaVerda Lisa Shinefeld Nancy Best Johny Lisitu Gary Tambolleo Yli Remo Vallejo 《Transfusion》2021,61(9):2710-2717